BLCO

Bausch + Lomb Corp

Add to Watchlist

Advanced Chart

11.760

-0.040(-0.340%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

11.910

Open

11.820

VWAP

11.76

Vol

370.55K

Mkt Cap

4.16B

Low

11.685

Amount

4.36M

EV/EBITDA(TTM)

15.87

Total Shares

351.48M

8.87B

EV/OCF(TTM)

53.43

P/S(TTM)

0.86

Bausch + Lomb Corporation is a Canada-based global eye health company. The Company’s Vision Care segment includes both a contact lens business and a consumer eye care business that consists of contact lens care products, over the counter (OTC) eye drops and eye vitamins. The Company’s Ophthalmic Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Its Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. The Company’s brands include PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, and many more.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

1.34B

+4.92%

0.287

+14.82%

1.25B

+4.77%

0.168

-0.98%

1.26B

+3.8%

0.118

-8.98%

Estimates Revision

The market is revising Downward the revenue expectations for Bausch + Lomb Corporation (BLCO) for FY2025, with the revenue forecasts being adjusted by -0.56% over the past three months. During the same period, the stock price has changed by -28.07%.

Revenue Estimates for FY2025

Revise Downward

-0.56%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-17.75%

In Past 3 Month

Stock Price

Go Down

-28.07%

In Past 3 Month

11 Analyst Rating

30.10% Upside

Wall Street analysts forecast BLCO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLCO is 15.30 USD with a low forecast of 11.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

7 Hold

1 Sell

Hold

30.10% Upside

Current: 11.760

Low

11.00

Averages

15.30

High

22.00

30.10% Upside

Current: 11.760

Low

11.00

Averages

15.30

High

22.00

HC Wainwright & Co.

Yi Chen

Strong Buy

Maintains

$20 → $15

2025-05-02

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$20 → $15

2025-05-02

Maintains

Strong Buy

Reason

Evercore ISI Group

Vijay Kumar

Buy

Maintains

$19 → $16

2025-05-01

Reason

Evercore ISI Group

Vijay Kumar

Price Target

$19 → $16

2025-05-01

Maintains

Buy

Reason

Wells Fargo

Larry Biegelsen

Hold

Maintains

$15 → $12

2025-05-01

Reason

Wells Fargo

Larry Biegelsen

Price Target

$15 → $12

2025-05-01

Maintains

Hold

Reason

Wells Fargo analyst Larry Biegelsen lowered the firm's price target on Bausch + Lomb to $12 from $15 and keeps an Equal Weight rating on the shares. The firm notes the company reported Q1 sales/EPS below the Street and updated FY25 guidance to reflect the enVista recall and improving FX, but no tariff impact.

Citigroup

Joanne Wuensch

Hold

Maintains

$14 → $13

2025-05-01

Reason

Citigroup

Joanne Wuensch

Price Target

$14 → $13

2025-05-01

Maintains

Hold

Reason

Citi lowered the firm's price target on Bausch + Lomb to $13 from $14 and keeps a Neutral rating on the shares following the Q1 report. The firm says that while not in the company's guidance, it includes a $20M EBITDA tariff impact in the model.

Needham

David Saxon

Hold

Reiterates

n/a

2025-04-24

Reason

Needham

David Saxon

Price Target

n/a

2025-04-24

Reiterates

Hold

Reason

RBC Capital

Douglas Miehm

Buy

Maintains

$18 → $17

2025-04-04

Reason

RBC Capital

Douglas Miehm

Price Target

$18 → $17

2025-04-04

Maintains

Buy

Reason

After Bausch + Lomb announced a voluntary recall of its enVista intraocular lenses, RBC Capital says talks with management indicated that it remains too early to determine the financial impact. However, the firm's view is the event may lead to a charge in Q1 and a negative impact on surgery group operations until the products are returned to the market, based on similar recalls that have occurred at other companies. The current stock price decline of 6% reflects a market cap erosion of about $330M, which is higher than the $184M enterprise value that RBC ascribes to the entire surgical segment, notes the analyst, who views the stock price reaction as "likely overdone." RBC has an Outperform rating and $18 price target on B+L shares.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Bausch + Lomb Corp (BLCO.N) is 17.16, compared to its 5-year average forward P/E of 21.74. For a more detailed relative valuation and DCF analysis to assess Bausch + Lomb Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

21.74

Current PE

17.16

Overvalued PE

25.92

Undervalued PE

17.56

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

10.68

Current EV/EBITDA

9.64

Overvalued EV/EBITDA

11.47

Undervalued EV/EBITDA

9.90

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Undervalued

5Y Average PS

1.32

Current PS

0.80

Overvalued PS

1.52

Undervalued PS

1.12

Financials

Annual

Quarterly

FY2025Q1

YoY :

+3.46%

1.14B

Total Revenue

FY2025Q1

YoY :

-506.67%

-61.00M

Operating Profit

FY2025Q1

YoY :

+29.45%

-211.00M

Net Income after Tax

FY2025Q1

YoY :

+25.00%

-0.60

EPS - Diluted

FY2025Q1

YoY :

+419.23%

-135.00M

Free Cash Flow

FY2025Q1

YoY :

-5.43%

51.72

Gross Profit Margin - %

FY2025Q1

YoY :

+14.47%

-3.48

FCF Margin - %

FY2025Q1

YoY :

+25.15%

-18.56

Net Margin - %

FY2025Q1

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

19.9K

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

2.6M

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

7.1M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

19.9K

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

BLCO News & Events

Events Timeline

2025-05-07 (ET)

2025-05-07

07:54:50

Bausch + Lomb announces CE Mark approval for LuxLife

2025-04-30 (ET)

2025-04-30

10:00:28

Bausch + Lomb falls -19.1%

2025-04-30

09:47:42

Bausch + Lomb falls -14.7%

News

5.0

05-16Benzinga

Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%

7.0

05-13Globenewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO

7.0

05-12PRnewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO

People Also Watch

Harmony Gold Mining Company Ltd

Merit Medical Systems Inc

Americold Realty Trust Inc

Hims & Hers Health Inc

FAQ

What is Bausch + Lomb Corp (BLCO) stock price today?

The current price of BLCO is 11.76 USD — it has decreased -0.34 % in the last trading day.

BLCO

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

BLCO News & Events

Events Timeline

News

People Also Watch

FAQ

What is Bausch + Lomb Corp (BLCO) stock price today?

What is Bausch + Lomb Corp (BLCO)'s business?

What is the price predicton of BLCO Stock?

What is Bausch + Lomb Corp (BLCO)'s revenue for the last quarter?

What is Bausch + Lomb Corp (BLCO)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Bausch + Lomb Corp (BLCO)'s fundamentals?

How many employees does Bausch + Lomb Corp (BLCO). have?

What is Bausch + Lomb Corp (BLCO) market cap?